Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study

BACKGROUND: The NEJ026 Phase 3 study demonstrated that erlotinib and bevacizumab (BE)-treated NSCLC patients with EGFR mutations had significantly better progression-free survival (PFS) than those treated with erlotinib alone (E). This study included a prospective analysis of the relationship betwee...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:EBioMedicine
Κύριοι συγγραφείς: Fukuhara, Tatsuro, Saito, Haruhiro, Furuya, Naoki, Watanabe, Kana, Sugawara, Shunichi, Iwasawa, Shunichiro, Tsunezuka, Yoshio, Yamaguchi, Ou, Okada, Prof Morihito, Yoshimori, Kozo, Nakachi, Ichiro, Gemma, Prof Akihiko, Azuma, Koichi, Kurimoto, Futoshi, Tsubata, Yukari, Fujita, Yuka, Nagashima, Hiromi, Asai, Gyo, Watanabe, Satoshi, Miyazaki, Masaki, Hagiwara, Prof Koichi, Nukiwa, Prof Toshihiro, Morita, Prof Satoshi, Kobayashi, Prof Kunihiko, Maemondo, Prof Makoto
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Elsevier 2020
Θέματα:
Research paper
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7334809/
https://ncbi.nlm.nih.gov/pubmed/32629391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102861
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια